How to optimize drug delivery in renal replacement therapy

Seminars in Dialysis

Volumn 24, Issue 2, 2011, Pages 176-182

  Awdishu, Linda ^a   Bouchard, Josée ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; HEMODIALYSIS FLUID;

ACUTE KIDNEY FAILURE; ADSORPTION; ANIMAL; ARTICLE; ARTIFICIAL MEMBRANE; BIOAVAILABILITY; HEMOFILTRATION; HUMAN; METABOLIC CLEARANCE RATE; METABOLISM; MICROBIOLOGICAL EXAMINATION; PROTEIN BINDING; RENAL REPLACEMENT THERAPY;

ACUTE KIDNEY INJURY; ADSORPTION; ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; HEMODIALYSIS SOLUTIONS; HEMOFILTRATION; HUMANS; MEMBRANES, ARTIFICIAL; METABOLIC CLEARANCE RATE; MICROBIAL SENSITIVITY TESTS; PROTEIN BINDING; RENAL REPLACEMENT THERAPY;

EID: 79955088415     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2011.00826.x     Document Type: Article

References (32)

1. Heintz BH, Matzke GR, Dager WE: Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 29:562-577, 2009
2. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C: Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 294:813-818, 2005
3. Odar-Cederlof I, Borga O: Kinetics of diphenylhydantoin in uraemic patients: consequences of decreased plasma protein binding. Eur J Clin Pharmacol 7:31-37, 1974
4. Winters M: Basic Clinical Pharmacokinetics. Washington: Lippincott, Williams & Wilkins, 1999
5. Susla GM: The impact of continuous renal replacement therapy on drug therapy. Clin Pharmacol Ther 86:562-565, 2009
6. Churchwell MD, Mueller BA: Drug dosing during continuous renal replacement therapy. Semin Dial 22:185-188, 2009
7. Schetz M: Drug dosing in continuous renal replacement therapy: general rules. Curr Opin Crit Care 13:645-651, 2007
8. Barbour A, Scaglione F, Derendorf H: Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/pharmacodynamic indices. Int J Antimicrob Agents 35:431-438, 2010
9. Bohler J, Donauer J, Keller F: Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage. Kidney Int Suppl 72:S24-S28, 1999
10. Bouman CS: Antimicrobial dosing strategies in critically ill patients with acute kidney injury and high-dose continuous veno-venous hemofiltration. Curr Opin Crit Care 14:654-659, 2008
11. Di Paolo A, Malacarne P, Guidotti E, Danesi R, Del Tacca M: Pharmacological issues of linezolid: an updated critical review. Clin Pharmacokinet 49:439-447, 2010
12. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC Jr, Craig WA, Billeter M, Dalovisio JR, Levine DP: Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy 29:1275-1279, 2009
13. Bugge JF: Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients. Acta Anaesthesiol Scand 45:929-934, 2001
14. Dromgoole SH: The binding capacity of albumin and renal disease. J Pharmacol Exp Ther 191:318-323, 1974
15. Bowmer CJ, Lindup WE: Investigation of the drug-binding defect in plasma from rats with glycerol-induced acute renal failure. J Pharmacol Exp Ther 210:440-445, 1979
16. Huang Z, Gao D, Letteri JJ, Clark WR: Blood-membrane interactions during dialysis. Semin Dial 22:623-628, 2009
17. Petitclerc T: Estimation of mass transfer through a hemodialyzer: theoretical approach and clinical applications. Artif Organs 22:601-607, 1998
18. Bayliss G: Dialysis in the poisoned patient. Hemodial Int 14:158-167, 2010
19. Okabe H, Higashi T, Ohta T, Hashimoto Y: Intestinal absorption and hepatic extraction of propranolol and metoprolol in rats with bilateral ureteral ligation. Biol Pharm Bull 27:1422-1427, 2004
20. Tanabe H, Taira S, Taguchi M, Hashimoto Y: Pharmacokinetics and hepatic extraction of metoprolol in rats with glycerol-induced acute renal failure. Biol Pharm Bull 30:552-555, 2007
21. Okabe H, Hasunuma M, Hashimoto Y: The hepatic and intestinal metabolic activities of P450 in rats with surgery- and drug-induced renal dysfunction. Pharm Res 20:1591-1594, 2003
22. Moon YJ, Lee AK, Chung HC, Kim EJ, Kim SH, Lee DC, Lee I, Kim SG, Lee MG: Effects of acute renal failure on the pharmacokinetics of chlorzoxazone in rats. Drug Metab Dispos 31:776-784, 2003
23. Lee AK, Lee JH, Kwon JW, Kim WB, Kim SG, Kim SH, Lee MG: Pharmacokinetics of clarithromycin in rats with acute renal failure induced by uranyl nitrate. Biopharm Drug Dispos 25:273-282, 2004
24. Choi G, Gomersall CD, Tian Q, Joynt GM, Freebairn R, Lipman J: Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med 37:2268-2282, 2009
25. Bouman CS, van Kan HJ, Koopmans RP, Korevaar JC, Schultz MJ, Vroom MB: Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing. Intensive Care Med 32:2013-2019, 2006
26. Brunet S, Leblanc M, Geadah D, Parent D, Courteau S, Cardinal J: Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am J Kidney Dis 34:486-492, 1999
27. Li AM, Gomersall CD, Choi G, Tian Q, Joynt GM, Lipman J: A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data? J Antimicrob Chemother 64:929-937, 2009
28. Joy MS, Matzke GR, Armstrong DK, Marx MA, Zarowitz BJ: A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother 32:362-375, 1998
29. Churchwell MD, Pasko DA, Mueller BA: Daptomycin clearance during modeled continuous renal replacement therapy. Blood Purif 24:548-554, 2006
30. Gwilt PR, Perrier D: Plasma protein binding and distribution characteristics of drugs as indices of their hemodialyzability. Clin Pharmacol Ther 24:154-161, 1978
31. Golestaneh L, Gofran A, Mokrzycki MH, Chen JL: Removal of vancomycin in sustained low-efficiency dialysis (SLED): a need for better surveillance and dosing. Clin Nephrol 72:286-291, 2009
32. Mushatt DM, Mihm LB, Dreisbach AW, Simon EE: Antibiotic dosing in slow extended daily dialysis. Clin Infect Dis 49:433-437, 2009